Valuation: Alteogen Inc

Market Cap 22,317B 16.13B 16.13B 13.82B 12.93B 11.82B 22.31B 1,544B 22.55B 153B 59.5B 776B 60.56B 59.25B 2,566B P/E 2026 *
75.3x
P/E 2027 * 55.7x
Enterprise Value 21.81B 15.76M 15.76M 13.51M 12.64M 11.55M 21.8M 1.51B 22.03M 150M 58.14M 758M 59.18M 57.9M 2.51B EV / Sales 2026 *
45.4x
EV / Sales 2027 * 32.9x
Free-Float
51.19%
Yield 2026 *
0.15%
Yield 2027 * 0.14%
Manager TitleAgeSince
Chief Executive Officer 61 26/12/2025
Director of Finance/CFO 61 28/03/2023
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 71 13/05/2008
Director/Board Member 70 29/03/2021
Director/Board Member 61 28/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.66%+2.80%+40.55%-0.33% 82.73B
-4.30%+115.47%+412.13%+23.29% 55.45B
+2.68%+10.02%-19.76%-34.08% 57.94B
+1.42%+1.61%-0.67%+34.08% 52.57B
+1.23%+2.49%+10.80%+172.65% 48.94B
+0.62%+4.29%+56.57%-16.88% 32.23B
+0.13%+3.63%+50.49%+99.25% 25.94B
+0.60%+3.57%+0.15%+196.15% 22.1B
+2.15%-0.86%+58.72%+108.04% 16.55B
Average +1.24%+17.75%+67.66%+64.69% 43.83B
Weighted average by Cap. +1.20%+22.00%+75.20%+44.84%

Financials

2026 *2027 *
Net sales 481B 348M 348M 298M 279M 255M 481M 33.28B 486M 3.3B 1.28B 16.71B 1.3B 1.28B 55.28B 655B 474M 474M 406M 380M 347M 655M 45.34B 662M 4.49B 1.75B 22.77B 1.78B 1.74B 75.34B
Net income 299B 216M 216M 185M 173M 158M 299M 20.7B 302M 2.05B 797M 10.39B 812M 794M 34.39B 373B 270M 270M 231M 216M 198M 373M 25.83B 377M 2.56B 995M 12.97B 1.01B 991M 42.92B
Net Debt -510B -368M -368M -316M -295M -270M -509M -35.27B -515M -3.49B -1.36B -17.71B -1.38B -1.35B -58.59B -765B -553M -553M -474M -443M -405M -764M -52.91B -772M -5.24B -2.04B -26.57B -2.07B -2.03B -87.91B
Logo Alteogen Inc
Alteogen Inc is a Korea-based company primarily engaged in the research, development, and sales of biopharmaceuticals. The Company develops, produces, and sells biopharmaceuticals, including biobetters and novel biopharmaceuticals, based primarily on hyaluronidase protein engineering technology, sustained-release biopharmaceutical technology, and next-generation antibody-drug conjugate technology. In addition, the Company is engaged in research, development, and commercialization of biosimilars.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-